PTGIR and pulmonary arterial hypertension: Endothelin receptor antagonist (ERA), phosphodiesterase 5 inhibitor (PDE-5i), prostaglandin I2 (PGI2), soluble guanylate cyclase stimulator (sGCS), and selective non-prostanoid prostacyclin receptor agonist (sPRA) are common choices for PAH with diverse mechanism.